Alembic Pharma Gets USFDA Final Approval for Venetoclax Tablets
Alembic Pharmaceuticals received USFDA final approval for Venetoclax Tablets (10mg, 50mg, 100mg). This approval, potentially eligible for 180-day exclusivity, targets a US market estimated at $1,584 million. This marks Alembic's 228th final ANDA approval from the USFDA.
USFDA approval for a drug with a substantial market size ($1,584 million) and potential for exclusivity directly impacts revenue and market share, signifying a high impact.
The USFDA final approval for a key drug product is a significant positive development for the company, indicating market potential and strengthening its product portfolio.
Alembic Pharmaceuticals Limited announced on October 30, 2026, that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Venetoclax Tablets in 10 mg, 50 mg, and 100 mg strengths.
The approved ANDA is therapeutically equivalent to Venclexta Tablets from AbbVie Inc. Venetoclax tablets are indicated for treating adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and in combination therapy for newly diagnosed acute myeloid leukemia (AML) in older adults or those with comorbidities that prevent intensive induction chemotherapy.
Alembic was a first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for these strengths, potentially making it eligible for 180 days of generic drug exclusivity. The estimated market size for Venetoclax tablets in the United States was US $1,584 million for the twelve months ending June 2026, according to IQVIA.
This approval brings Alembic's total cumulative ANDA approvals from the USFDA to 248, comprising 228 final approvals and 20 tentative approvals. The company has been a significant player in the healthcare sector since 1907, with a global presence in manufacturing and marketing generic pharmaceutical products.
What to do with a filing like this
Alembic Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alembic Pharmaceuticals Limited. Read the original for the full detail.